How quickly does Wegovy work — and what should you actually expect?

Week one: you've taken the pen out of the fridge, now what?

The pen is in the sharps bin, you've logged the date, and you're watching for something to happen. For most people, the first shift isn't on the scales, it's at the table. Within the opening week or two, semaglutide begins signalling satiety to receptors in the brain and gut, and many people find they feel full earlier in a meal, or simply think about food less between them. That's the GLP-1 mechanism at work: the medicine mimics a hormone your body already produces after eating, stretching that 'enough' signal across the hours that follow.

What you're unlikely to feel at 0.25 mg is dramatic weight loss. The starting dose exists primarily to let your body adapt, to reduce the nausea and digestive discomfort that come with the territory at higher doses. Think of it as the system settling in rather than the treatment beginning in earnest. The mechanism behind how Wegovy works takes time to build its full effect, and that's by design. Some people do notice a modest drop in weight in the first month; others see very little and worry the medicine isn't working. Both experiences are common.

Side effects, if they arrive, tend to peak in the first week or two after each dose step, nausea, loose stools, some fatigue. For most people these settle within days.

Weeks four to twenty: the titration phase is where results start to compound

This is the stretch that decides a lot. Every four weeks the dose steps up (0.25 mg to 0.5 mg, then 1.0 mg, 1.7 mg, and finally 2.4 mg) and with each increase the appetite-suppressing effect deepens. A question our prescribers hear most weeks is whether a plateau in weeks two or three means treatment has stopped working. It almost never does; it usually means the current dose has done what it can and the next step is due.

By weeks eight to twelve, most people on the titration schedule are seeing a measurable change on the scales. The precise early timeline varies by individual (starting weight, diet, activity, how well the GI side effects settle) but the clinical evidence is consistent: weight loss accelerates as the dose rises. The STEP 1 trial, published in the New England Journal of Medicine, followed adults at 2.4 mg semaglutide for 68 weeks and recorded an average body-weight reduction of around 15%, a figure that reflects cumulative progress across the full period, not a sudden drop.

Lifestyle changes matter here too. Wegovy is licensed for use alongside a reduced-calorie diet and increased physical activity. The medicine blunts hunger; what you do with that blunting shapes the result. Protein intake, hydration and keeping muscle mass through some resistance exercise all become more relevant once appetite is reduced.

Months five to sixteen: maintenance and what 'working' looks like long term

Reaching 2.4 mg is not the end of the story, it's closer to the beginning of the main chapter. At maintenance dose, weight loss continues for most people, often peaking somewhere between nine and sixteen months of treatment. The semaglutide evidence base is clear that the medicine works on a biological level; how much weight is lost depends on the person.

Wegovy holds a NICE recommendation (TA875) for use within specialist weight management services for a maximum of two years; if less than 5% of body weight has been lost after six months on the maintenance dose, continuing is clinically reviewed. The NHS England guidance on weight management injections sets out this stopping-rule clearly. Private patients follow the same clinical logic: progress is reviewed regularly, and treatment continues only where it remains appropriate.

The newer 7.2 mg dose, approved by the MHRA in April 2026, reported average weight loss of around 20.7% over 72 weeks in trials (approaching tirzepatide results) though this is the maximum dose and is not where treatment starts. Specific dose availability is confirmed at consultation, and those researching branded and unbranded options may find the Skinny Quick semaglutide page a useful reference point. For context on how Wegovy's cost compares across providers, the Wegovy pricing page covers what a private prescription typically includes.

When results feel slow: realistic expectations versus early warning signs

A slow start is not the same as no effect. Weight is a complex, biology-driven measure, hormones, sleep, stress, fluid retention and the timing of weigh-ins all introduce noise. Weighing weekly at the same time of day, rather than daily, gives a more honest picture.

That said, there are genuine signs that something may need clinical attention: persistent vomiting that makes it hard to eat or drink, severe stomach pain (especially pain that radiates toward the back, which the MHRA highlights as a potential sign of pancreatitis requiring urgent review), or a complete absence of any appetite change after several weeks at a stable dose. These are conversations for your prescriber, not adjustments to make independently. The pharmacology of semaglutide explains why individual variation is real and expected, rather than a sign treatment has failed.

For anyone considering treatment, exploring your options is the natural starting point, or if you're ready to speak to a clinician directly, start your free consultation and a GPhC-registered prescriber will review your details the same day.